EU Clinical Trial 2018-004707-40

Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years.  Feb 25, 2019

Main objective of the trial: •To demonstrate that PEP using the new "one-week, 4-site" (4-4-4-0-0) intradermal (ID) vaccination regimen is non-inferior to PEP using the updated TRC (2-2-2-0-2) ID vaccination regimen.

Parties

Sponsors
Countries
FR PH
Keywords
FAVIRAB®, purified Equine Rabies Immunoglobulin (pERIG) Verorab®: Purified Vero cell Rabies Vaccine (PVRV) Wistar rabies PM/WI 38 1503-3M strain purified Equine Rabies Immunoglobulin (pERIG)

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.